Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial enrolled 5 participants, all of whom completed the study — none dropped out. All participants received a treatment called Interferon Gamma-1b. The trial was measuring changes in the thickness of the central part of the retina (the macula, a small area at the back of the eye responsible for sharp, central vision) in two eyes: the "study eye" (the eye being treated) and the "fellow eye" (the other eye). These measurements were taken using a scanning technique called OCT, which creates detailed images of the eye's layers without any cuts or needles. Measurements were taken at the start of the trial (baseline) and again at one week and two weeks. The reported data shows that in the study eye, the central macular thickness decreased by an average of 38.60 micrometres (very small units of measurement) by week one, and by 47.40 micrometres by week two, compared to the starting measurement. In the fellow eye — which was not the focus of treatment — the reported data shows the thickness actually increased by an average of 12.00 micrometres at week one and 30.20 micrometres at week two. For the overall volume of the macula (measured in cubic millimetres), the study eye showed a very small average decrease of 0.02 cubic millimetres at week one, while the fellow eye showed a small average increase of 0.14 cubic millimetres at week one. Changes in macular volume at week two were not reported in the data. It is worth noting that with only 5 participants, this was a very small study, and no comparison group (such as a placebo group) was included in the reported data. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 16585190) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Uveitis Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You must be 18 years of age or older.
- You must be willing and able to read, understand, and sign a consent form for the study.
- You must have been diagnosed with swelling in the central part of the retina (a condition called CME) caused by eye inflammation (uveitis) in at least one eye, confirmed by a special eye scan.
- You must be willing to follow all study procedures and be able to attend all required appointments.
- You must have a vision level of at least 20/400 (some usable vision) in the eye being studied.
- If you are a woman who could become pregnant, you must not currently be pregnant or breastfeeding.
- If you could become pregnant or father a child, you must agree to use two approved forms of birth control during the study and for six weeks after the last dose of the study treatment (acceptable methods include birth control pills, hormonal injections, skin patches, vaginal rings, an IUD, barrier methods with spermicide, or permanent surgical options).
Who may not be able to join:
- You may not be eligible if you are unable to tolerate eye drops or follow the study's required procedures.
- You may not be eligible if you currently have a significant active infection that your doctor believes would make it unsafe for you to participate.
- You may not be eligible if you have been diagnosed with multiple sclerosis (MS), as the study treatment could potentially make MS worse.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Change in Excess Central Macular Thickening in the Study Eye, as Measured by Optical Coherence Tomography (OCT), at Week One Compared to Baseline
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.